Warburg Pincus-Backed AI Drug Firm Insilico Weighs U.S. IPO
- Hong Kong firm in talks with banks on potential share sale
- Company could seek to raise about $300 million from listing
This article is for subscribers only.
Insilico Medicine, a company that uses artificial intelligence to drive drug discovery, is considering a U.S. initial public offering that could raise about $300 million, according to people familiar with the matter.
The Hong Kong-based firm is in talks with investment banks about a possible first-time share sale as soon as later this year, the people said, asking not to be identified because the matter is private.